Antithrombotic compound

1. A compound of the formula (I)

wherein R is independently SO 3 − or CH 3 ;

the spacer is represented by *—(CH 2 CH 2 O) p —(CH 2 )—NH—C(O)—(CH 2 ) n —NH—C(O)—(CH 2 ) m —, wherein * indicates the end attached to the pentacaccharide residue,

p is 1-5,

n is 1-5 and

m is 1 or 2;

the charge of the pentasaccharide residue is compensated by positively charged counterions; and

and the total number of sulfate groups in the pentasaccharide residue is 4, 5 or 6;

or a pharmaceutically acceptable salt, a prodrug or solvate thereof.

2. The compound of claim 1 , wherein the pentasaccharide residue has the structure

3. The compound of claim 1 , wherein the spacer is *—(CH 2 CH 2 O) 3 —(CH 2 ) 2 —NH—C(O)—(CH 2 ) 3 —NH—C(O)—CH 2 —, the indicated with * being attached to the pentasaccharide residue.

4. The compound of claim 1 having the structure

5. A process for the preparation of formula I,

wherein R is independently SO 3 − or CH 3 ;

the spacer is represented by *—(CH 2 CH 2 O) p —(CH 2 )—NH—C(O)—(CH 2 ) n —NH—C(O)—(CH 2 ) m —, wherein * indicates the end attached to the pentacaccharide residue,

p is 1-5,

n is 1-5 and

m is 1 or 2;

the charge of the pentasaccharide residue is compensated by positively charged counterions; and

and the total number of sulfate groups in the pentasaccharide residue is 4, 5 or 6 comprising:

reacting an intermediate compound containing a benzamidine moiety precursor, said benzamidine moiety precursor represented by formula (II)

wherein R′—R″— —C(O)O—;

with a pentasaccharide containing reactant represented by formula (IIIa)

6. A pharmaceutical composition, comprising:

the compound of claim 1 and

pharmaceutically suitable auxiliaries.

7. A method of treating thrombosis of thrombosis-related diseases in a patient, comprising:

administering an effective amount to said patient of the compound according to claim 1 and

pharmaceutically suitable auxiliaries.

8. The compound of claim 1 , wherein p=3.